Clinuvel Pharmaceuticals Limited

Hello everyone, thank you for joining Plinuvel's investor webinar today. I am Stella Maris of Monsoon Communications. In today's webinar, Plinuvel will share their half-year results and operational highlights for the six months ended on 31st December 2024. Many have asked questions as you registered for the webinar, which may still be tabled during the session through the Q&A function. I will now hand over to Malcolm Poole, Head of Investor Relations and Australian Operations, to conduct the proceedings.

Thank you, Stella, and we do appreciate Monsoon Communications' ongoing assistance in these presentations and welcome to the over 200 participants to the webinar. Joining me today is Peter Vaughan, Chief Financial Controller and Lachlan Hay, our Chief Operations Officer. Before we discuss the financial results and operational highlights, as Stella said, for the half year to 31 December 2024, just a few formalities. First, our forward-looking statement. I don't expect you to read all this, but many of you will be familiar with this type of statement, and that is that there is a number of risks that can materialise that can impact upon the plans of the company, and you should take those into account in your ongoing assessment of Cliniavel. Second, all references to dollars are Australian dollars, the reporting currency of the company. And third, when comparisons are made in terms of change, they are to the corresponding period of the prior year of 2023. Now, we posted a great set of numbers today, but I'm not going to steal the thunder of the Chief Financial Officer, and I'll invite Peter to overview the key achievements.

Thanks Malcolm. Look again, we've posted another fantastic result for this half year. Strong underlying profit figures and if we look at the numbers more closely, our sales grew by 10.5% to $36 million. Our total revenues grew by 21% to $43 million. We had expenses growth that was well contained to a modest 2% increase. Our profit before tax rose by 48% to just under $22 million and our profit after tax increased by almost 30% to $14 million. We saw a 27% rise in earnings per share from 22 cents for the corresponding period to 28 cents per share for the current period. Our balance sheet strengthened with a 7% increase in net assets since June last year. And our cash reserves rose by 8% to $198 million.